AllSci News
Rochester Uni backed by NIH to explore PKD3 as cardiac therapeutic target
University of Rochester has received a USD 2.38 million NIH R01 grant from the National Heart, Lung, and Blood Institute (NHLBI) to investigate how protein...
Lilly's RNA partner Rznomics joins Lilly Gateway Labs
South Korea-based Rznomics Inc. (KOSDAQ: 476830) has joined Lilly Gateway Labs in San Diego, deepening a relationship with Eli Lilly and Company that began...
Protein charge emerges as key constraint for AI-designed cancer minibinders
A study from researchers at the University of Bonn demonstrates that the isoelectric point (pI) of AI-designed protein minibinders — not just their binding...
AKR1A1 loss exposes metabolic vulnerability in drug-resistant liver, kidney cancers
Loss of a metabolic enzyme found in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) creates a selective dependence on a detoxification pathway...
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m
Alvotech (Nasdaq: ALVO) has licensed US and Asian commercialization rights for two biosimilar candidates — AVT34, a proposed biosimilar to durvalumab...
VectorBuilder, Lir apply AI to optimize AAV capsids for manufacturing
Chicago-based VectorBuilder and Ireland-based Lir Therapeutics have announced a joint platform collaboration to engineer adeno-associated virus (AAV)...
METiS, WestVac team up on AI-designed personalized mRNA cancer vaccines
METiS TechBio (HKEX: 7666) and China-based WestVac Biopharma have signed a strategic cooperation framework agreement to jointly develop personalized mRNA...
Ambros lands USD 150m financing in Werewolf reverse merger to fund neridronate Phase III
San Diego-based Ambros Therapeutics is merging with Waltham, Massachusetts-based Werewolf Therapeutics (Nasdaq: HOWL) in an all-stock transaction, with a...
FDA sets cross-center framework for digital measures in clinical trials
Category: Clinical Trial Reform | Regulatory Body: FDA (CBER, CDER, CDRH, OCE) | Geography: United States | Instrument: Guidance document
Gossamer secures up to USD 250m to fund seralutinib through uncertain FDA path
San Diego-based Gossamer Bio (Nasdaq: GOSS) announced a structured private placement of up to USD 250 million, with USD 150 million in committed capital,...
Bristol Myers Squibb taps Chai Discovery's generative AI for antibody design across portfolio
San Francisco-based Chai Discovery and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to apply Chai's generative AI antibody discovery...
Adaptin Bio opens first-in-human trial of brain-targeted EGFRvIII T cell engager
Enrollment has opened in a first-in-human Phase I trial of APTN-101, a bispecific T cell engager developed by Charlotte, North Carolina-based Adaptin Bio,...
CStone to put EGFR/HER3 bispecific ADC to first-in-human test in China
China's National Medical Products Administration (NMPA) has cleared CStone Pharmaceuticals (HKEX: 2616) to begin clinical trials of CS5007, an EGFR/HER3...
Akeso advances third ADC into clinical trials with B7-H3-targeting AK157D1
China-based Akeso (HKEX: 9926.HK) has received clearance from China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to...
Luye Pharma advances therapeutic mRNA vaccine into Phase II for HPV lesions
Luye Pharma Group (HKEX: 02186) is advancing its LY01620 mRNA vaccine into Phase II trials in China for HPV16-positive cervical high-grade squamous...
The AllSci Brief
Free, systematic R&D and deal news. Daily.